Nanobody Lab

• Use of nanobodies to manipulate (intracellular) protein function, given that pharmacological inhibitors are wanting for the majority of polypeptides.
• Target proteins are involved in cancer, signal transduction or amyloid disorders
• Improvement of nanobody technology by converting nanobodies into a specificity key charged with a payload (antibody drug conjugate) by incorporating non-standard amino acids 

Gulliver Biomed is a spin-off company from the Nanobody Lab.

More information about the Nanobody Lab

• Publications
• Doctoral dissertations

More information about Prof. Jan Gettemans

• Cancer Research Institute Ghent (CRIG Group Leader)
• Belgian Society for Biochemistry and Molecular Biology